Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation

James Todd Auman, Robert Church, Soo Youn Lee, Mark A. Watson, James W. Fleshman, Howard L. Mcleod

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Cancer cells treated with the cyclooxygenase-2 inhibitor celecoxib show growth inhibition and induced apoptosis. This study was conducted to determine if the same processes are relevant to celecoxib's effects on human colorectal adenocarcinomas treated in vivo. A cohort of 23 patients with primary colorectal adenocarcinomas was randomised to receive a 7-d course of celecoxib (400 mg b.i.d.) or no drug prior to surgical resection. Gene expression profiling was performed on resected adenocarcinomas from the cohort of patients. Using fold change (>1.5) and p-value (<0.05) cut-offs, 190 genes were differentially expressed between adenocarcinomas from patients receiving celecoxib and those that did not. The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation. Celecoxib pre-treatment for 7 d in vivo is associated with alterations in colorectal adenocarcinoma gene expression which are suggestive of diminished cellular proliferation.

Original languageEnglish
Pages (from-to)1754-1760
Number of pages7
JournalEuropean Journal of Cancer
Volume44
Issue number12
DOIs
StatePublished - Aug 2008

Keywords

  • Celecoxib
  • Colorectal neoplasms
  • Cyclooxygenase 2 inhibitors
  • Gene expression profiling
  • cDNA microarrays

Fingerprint

Dive into the research topics of 'Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation'. Together they form a unique fingerprint.

Cite this